According to AIM Vaccine (06660.HK), Vice President and Chief Research Officer Zhang Fan, and General Manager of AIM Lifanda Peng Yucai, recently published the preclinical research data of the mRNA rabies vaccine LVRNA001 in the international authoritative academic journal "npj Vaccines": Only two vaccinations are needed to provide 100% safe and effective immune protection. This has laid a solid foundation for the next stage of research on human rabies mRNA vaccines.

The paper published in the international authoritative academic journal "npj Vaccines" fully demonstrates the advantages and features of LVRNA001 from the aspects of preclinical safety and effectiveness.

Protection efficacy tests for dogs and mice pre exposure immunization and post exposure immunization indicate that one or two immunizations with LVRNA001 can stimulate the production of higher levels of protective neutralizing antibodies at a faster speed, showing higher protection efficacy against ultra-high doses of rabies virus attacks compared to the five-dose inactivated vaccine.

Safety assessment is a mandatory requirement for Investigational New Drug (IND) applications. In acute toxicity studies in mice, single immunization with LVRNA001 (10 or 50 μg) does not cause significant toxic signs. Repeated dose toxicity studies in crab-eating macaques also show good tolerance at both low and high doses. At the same time, reproductive toxicity studies in rats indicate that LVRNA001 administration does not affect pregnant rats or their offspring, nor does it produce reproductive or developmental toxicity.

Overall, the LVRNA001 under R&D by AIM Vaccine can produce higher levels of protective neutralizing antibodies at a faster speed and provide in vivo protection, while showing good safety, indicating that LVRNA001 is a promising candidate vaccine for rabies.

According to the company's previous announcements, AIM Vaccine is one of the earliest enterprises in China to develop mRNA vaccine products and is also one of the first domestic vaccine enterprises to obtain independent patents for mRNA technology, with a mature mRNA vaccine R&D system, having developed several mRNA candidate vaccines, including rabies, respiratory syncytial virus (RSV) and shingles. Currently, AIM has established a comprehensive mRNA vaccine quality management system and a commercial-scale production workshop that meets GMP standards, and vaccines produced on the mRNA technology platform have also been clinically validated.